var data={"title":"Alteplase: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Alteplase: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5595?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=alteplase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Alteplase: Patient drug information&quot;</a> and <a href=\"topic.htm?path=alteplase-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Alteplase: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132252\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Activase;</li>\n      <li>Cathflo Activase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132253\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Activase rt-PA;</li>\n      <li>Cathflo Activase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132301\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Thrombolytic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50663670\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute ischemic stroke:</b> Activase: IV: Within 3 hours of the onset of symptom onset (labeled use) <b>or</b> within 3 to 4.5 hours of symptom onset (off-label use; AHA/ASA [Jauch 2013]; Hacke 2008; Powers 2015): <b>Note:</b> Perform noncontrast-enhanced CT or MRI prior to administration. Initiation of anticoagulants (eg, heparin) or antiplatelet agents (eg, aspirin) within 24 hours after starting alteplase is not recommended; however, initiation of aspirin within 24 to 48 hours after stroke onset is recommended (AHA/ASA [Jauch 2013]). Initiation of SubQ heparin (&le;10,000 units) or equivalent doses of low molecular weight heparin for prevention of DVT during the first 24 hours of the 3- to 4.5-hour window trial did not increase incidence of intracerebral hemorrhage (Hacke 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Recommended total dose: 0.9 mg/kg (maximum total dose: 90 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients &le;100 kg:</i> Load with 0.09 mg/kg (10% of 0.9 mg/kg dose) as an IV bolus over 1 minute, followed by 0.81 mg/kg (90% of 0.9 mg/kg dose) as a continuous infusion over 60 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients &gt;100 kg:</i> Load with 9 mg (10% of 90 mg) as an IV bolus over 1 minute, followed by 81 mg (90% of 90 mg) as a continuous infusion over 60 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute peripheral arterial occlusion (off-label use):</b> Intra-arterial:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Weight-based regimen:</i> 0.001 to 0.02 mg/kg/hour (maximum dose: 2 mg/hour) (Semba 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Fixed-dose regimen:</i> 0.12 to 2 mg/hour (Semba 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The ACC/AHA guidelines state that thrombolysis is an effective and beneficial therapy for those with acute limb ischemia (Rutherford categories I and IIa) of &lt;14 days' duration (Hirsch 2006). The optimal dosage and concentration has not been established; a number of intra-arterial delivery techniques are employed with continuous infusion being the most common (Ouriel 2004). The Advisory Panel to the Society for Cardiovascular and Interventional Radiology on Thrombolytic Therapy recommends dosing of &le;2 mg/hour and concomitant administration of subtherapeutic heparin (aPTT 1.25 to 1.5 &times; baseline) (Semba 2000). Duration of alteplase infusion dependent upon size and location of the thrombus; typically between 6 to 48 hours (Disini 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Central venous catheter clearance:</b> Cathflo Activase (1 mg/mL): Intracatheter:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients &lt;30 kg:</i> 110% of the internal lumen volume of the catheter, not to exceed 2 mg/2 mL; retain in catheter for 0.5 to 2 hours; may instill a second dose if catheter remains occluded.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients &ge;30 kg:</i> 2 mg/2 mL; retain in catheter for 0.5 to 2 hours; may instill a second dose if catheter remains occluded.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Frostbite (off-label use): Note:</b> For use in patients with deep frostbite injury with potential significant morbidity (eg, extending proximally to the proximal interphalangeal joints of digits), without contraindications to the use of alteplase, who present within 24 hours of injury. Use of alteplase in the field is not recommended; administer treatment in a facility capable of intensive-care monitoring (WMS [McIntosh 2014]). Additional data may be necessary to further define the role of alteplase in the treatment of frostbite.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intra-arterial: 2 to 4 mg bolus followed by a continuous intra-arterial infusion of 0.5 to 1 mg/hour (total dose if bilateral extremity involvement) via femoral or brachial artery; administer with continuous infusion heparin via an intra-arterial catheter. Discontinue alteplase if fibrinogen levels decrease to &lt;150 mg/dL, if reperfusion is complete (as evidenced by angiography), or after a period of 48 hours whether or not reperfusion is achieved (Bruen 2007; Ibrahim 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parapneumonic effusions and empyema (off-label use):</b> Intrapleural: 10 mg (diluted in 30 mL of NS) administered twice daily for a total of 3 days; each alteplase dose was followed &gt;2 hours later by an intrapleural dornase alfa dose (with a 1-hour dwell time for each drug) (Rahman 2011). Some clinicians suggest consideration of fibrinolytic use in patients in whom treatment with at least 24 hours of chest tube drainage has failed and who are poor surgical candidates (Hamblin 2010). Dosing for this indication has not been established. Alteplase monotherapy dosing regimens have varied (range: 10 to 100 mg) and produced conflicting results in small trials and case series. These regimens have also included variations in chest tube sizes, number of doses, patient positions (still vs rotation), and clamping durations (Thommi 2007; Thommi 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic valve thrombosis, right-sided (any size thrombus) or left-sided (thrombus area &lt;0.8 cm<sup>2</sup>, recent onset [&lt;14 days] of NYHA class I to II symptoms), or left-sided (thrombus area &ge;0.8 cm<sup>2</sup>) when contraindications to surgery exist (off-label use)</b> (ACCP [Guyatt 2012]; AHA/ACC [Nishimura 2014]; Alpert 2003; Roudaut 2003): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>High-dose regimen:</i> Load with 10 mg, followed by 90 mg over 90 to 180 minutes (without heparin during infusion)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Low-dose regimen (preferred for very small adults):</i> Load with 20 mg, followed by 10 mg/hour for 3 hours (without heparin during infusion)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> After successful administration of alteplase, heparin infusion should be introduced until warfarin achieves therapeutic INR (aortic: 3.0 to 4.0; mitral: 3.5 to 4.5) (Bonow 2008). The 2012 ACCP guidelines for antithrombotic therapy make no recommendation regarding INR range after prosthetic valve thrombosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary embolism (PE), acute (hemodynamically stable/submassive) (off-label use):</b> IV: Activase: 100 mg as an infusion over 2 hours. Institute or resume parenteral anticoagulation near the end of or immediately following the alteplase infusion when the partial thromboplastin time or thrombin time returns to twice normal or less. <b>Note:</b> Not recommended for most patients with acute PE without hypotension; use only in select patients showing signs of clinical deterioration despite maintaining a systolic BP &gt;90 mm Hg where benefits outweigh risks (Kearon 2012; Kearon 2016; Konstantinides 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary embolism (PE), acute (hemodynamically unstable/massive):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i> Activase: 100 mg as an infusion over 2 hours. Institute or resume parenteral anticoagulation near the end of or immediately following the alteplase infusion when the partial thromboplastin time or thrombin time returns to twice normal or less.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Catheter-directed thrombolysis (off-label): </i>24 mg administered either as 1 mg/hour for 24 hours via a unilateral catheter or as 1 mg/hour/catheter for 12 hours via bilateral catheters (Piazza 2015). <b>Note:</b> Due to insufficient evidence, catheter directed thrombolysis (CDT) is not recommended for acute PE unless there is access to the expertise and resources necessary to perform CDT; intravenous administration of a systemic thrombolytic is preferred (Kearon 2012; Kearon 2016; Wang 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary embolism (PE) associated with cardiac arrest (off-label use): </b>Activase: IV, Intraosseous (if IV access cannot be obtained): 50 mg bolus over 2 minutes; repeat a second 50 mg bolus 15 minutes later if return of spontaneous circulation (ROSC) is not achieved. Early administration is recommended when PE is presumed or confirmed. Systemic anticoagulation (eg, unfractionated heparin) should be administered with or shortly after administration of alteplase (AHA [Lavonas 2015]; Logan 2014). <b>Note:</b> When administered via intraosseous catheter, monitor for extravasation and subcutaneous bleeding at the intraosseous catheter insertion site (Landy 2012; Logan 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ST-elevation MI (STEMI):</b> Activase: IV: <b>Note:</b> Manufacturer's labeling recommends 3-hour infusion regimen; however, accelerated regimen preferred by the ACCF/AHA (O'Gara 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Accelerated regimen (weight-based):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients &gt;67 kg:</i> Total dose: 100 mg over 1.5 hours; administered as a 15 mg IV bolus over 1 to 2 minutes followed by infusions of 50 mg over 30 minutes, then 35 mg over 1 hour. Maximum total dose: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients &le;67 kg:</i> Infuse 15 mg IV bolus over 1 to 2 minutes followed by infusions of 0.75 mg/kg (not to exceed 50 mg) over 30 minutes then 0.5 mg/kg (not to exceed 35 mg) over 1 hour. Maximum total dose: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note: Thrombolytic should be administered within 30 minutes of hospital arrival. </b>Generally, there is only a small trend for benefit of therapy after a delay of 12 to 24 hours from symptom onset, but thrombolysis may be considered for selected patients with ongoing ischemic pain and extensive ST elevation; however, primary PCI is preferred in these patients. Administer concurrent aspirin, clopidogrel, and anticoagulant therapy (ie, unfractionated heparin, enoxaparin, fondaparinux) with alteplase (O'Gara 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132279\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=alteplase-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Alteplase: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Central venous catheter clearance:</b> Intracatheter:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients &lt;30 kg:</i> 110% of the internal lumen volume of the catheter, not to exceed 2 mg/2 mL; retain in catheter for 0.5 to 2 hours; may instill a second dose if catheter remains occluded</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients &ge;30 kg:</i> 2 mg/2 mL; retain in catheter for 0.5 to 2 hours; may instill a second dose if catheter remains occluded </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Parapneumonic effusions and empyema (off-label use):</b> Infants &gt;3 months, Children, and Adolescents: Intrapleural: 4 mg (diluted in 40 mL of normal saline), with the first dose administered at time of chest tube placement (with a 1-hour dwell time); repeat every 24 hours for a total of 3 doses; or 0.1 mg/kg (maximum: 3 mg) (diluted in 10 to 30 mL of normal saline), with the first dose administered after pigtail catheter (chest tube) placement (45- to 60-minute dwell time) and repeat doses administered every 8 hours for 3 days (total of 9 doses)  (Bradley 2011; Hawkins 2004; St Peter 2009). Dosing for this indication has not been established. Several intrapleural dosage regimens have been evaluated and have included variations in chest tube sizes, number of doses, patient positions (still vs rotation), and clamping durations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132258\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671450\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Plasma clearance is rapid and mediated primarily by the liver; therefore, degree of renal impairment is unlikely to influence elimination of alteplase. Hemostatic defects due to severe renal disease may increase the risk for bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Dialyzable: Unknown, but unlikely (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671451\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Plasma clearance is rapid and mediated primarily by the liver. Significant hepatic impairment and hemostatic defects due to severe hepatic disease may increase the risk for bleeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132234\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cathflo Activase: 2 mg (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Activase: 50 mg (1 ea); 100 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132219\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132237\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Activase:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>ST-elevation MI or acute ischemic stroke:</i> Administer bolus dose (prepared by one of three methods) over 1 minute followed by an infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infusion: Remaining dose for STEMI or AIS may be administered as follows: Any quantity of drug not to be administered to the patient must be removed from vial(s) prior to administration of remaining dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">50 mg vial: Either PVC bag or glass vial and infusion set</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">100 mg vial: Insert spike end of the infusion set through the same puncture site created by transfer device and infuse from vial.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If further dilution is desired, may be diluted in equal volume of 0.9% sodium chloride or D5W to yield a final concentration of 0.5 mg/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>PE, acute:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hemodynamically unstable/massive PE or hemodynamically stable/submassive PE (off-label use):</i> Administer as an IV infusion using a peripheral vein (Kearon 2012; Kearon 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>PE associated with cardiac arrest (off-label use)</i>: During cardiopulmonary resuscitation, administer as a rapid IV bolus over 2 minutes (AHA [Lavonas 2015]; B&ouml;ttiger 2001). When IV access cannot be established, some experts have suggested administration via intraosseous catheter; must monitor for extravasation and subcutaneous bleeding at the intraosseous catheter insertion site (Landy 2012; Logan 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intracatheter: Cathflo Activase: Instill dose into occluded catheter. Do not force solution into catheter. After a 30-minute dwell time, assess catheter function by attempting to aspirate blood. If catheter is functional, aspirate 4 to 5 mL of blood in patients &ge;10 kg or 3 mL in patients &lt;10 kg to remove Cathflo Activase and residual clots. Gently irrigate the catheter with NS. If catheter remains nonfunctional, let Cathflo Activase dwell for another 90 minutes (total dwell time: 120 minutes) and reassess function. If catheter function is not restored, a second dose may be instilled.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Intrapleural: <i>Parapneumonic pleural effusions and empyemas (off-label use):</i> Instill dose into chest tube and clamp drain. Although the optimum dwell time has not been determined, clinical trials more often have used either a 45-minute (Hawkins 2004) or 1-hour (Rahman 2011; St. Peter 2009) dwell time; after dwell period, release clamp and connect chest tube to continuous suction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471277\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 1 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Concentrations for some indications (eg, peripheral arterial occlusion) may require further dilution (eg, 0.1 to 0.2 mg/mL [Chan 2001; Semba 2000]) and a usual concentration may not be established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471278\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 0.5 mg/mL <b>or</b> 1 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132236\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Activase:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acute ischemic stroke: Treatment of acute ischemic stroke (AIS) as soon as possible but within 3 hours of symptom onset.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pulmonary embolism: Management of acute massive pulmonary embolism (PE)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ST-elevation myocardial infarction: Management of ST-elevation myocardial infarction (STEMI) for the lysis of thrombi in coronary arteries.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Limitations of use: The risk of stroke may outweigh the benefit produced by thrombolytic therapy in patients whose acute myocardial infarction (MI) puts them at low risk for death or heart failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended criteria for treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">STEMI (ACCF/AHA [O&rsquo;Gara 2013]): Ischemic symptoms within 12 hours of treatment or evidence of ongoing ischemia 12 to 24 hours after symptom onset with a large area of myocardium at risk or hemodynamic instability.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">STEMI ECG definition: New ST-segment elevation at the J point in at least 2 contiguous leads of &ge;2 mm (0.2 mV) in men or &ge;1.5 mm (0.15 mV) in women in leads V<sub>2</sub>-V<sub>3</sub> and/or of &ge;1 mm (0.1 mV) in other contiguous precordial leads or limb leads. New or presumably new left bundle branch block (LBBB) may interfere with ST-elevation analysis and should not be considered diagnostic in isolation.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">At non-PCI-capable hospitals, the ACCF/AHA recommends thrombolytic therapy administration when the anticipated first medical contact (FMC)-to-device time at a PCI-capable hospital is &gt;120 minutes due to unavoidable delays.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AIS: Onset of stroke symptoms within 3 hours of treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pulmonary embolism (PE), acute (hemodynamically unstable/massive): Acute PE in patients with sustained hypotension (SBP &lt;90 mm Hg for 15 minutes) or with signs/symptoms of shock and without a high bleeding risk (Kearon 2012; Kearon 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cathflo Activase: Restoration of function to central venous access device</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475022\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute ischemic stroke presenting 3 to 4.5 hours after symptom onset; Acute ischemic stroke (intra-arterial use [off-label route]); Frostbite; Parapneumonic pleural effusions and empyemas (adults); Parapneumonic pleural effusions and empyemas (pediatric patients &gt;3 months of age); Peripheral arterial occlusion; Prosthetic valve thrombosis; Pulmonary embolism, acute (hemodynamically stable/submassive); Pulmonary embolism associated with cardiac arrest; Retinal artery occlusion/retinal vein occlusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132309\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Activase may be confused with Cathflo Activase, TNKase</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alteplase may be confused with Altace</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&ldquo;tPA&rdquo; abbreviation should not be used when writing orders for this medication; has been misread as TNKase (tenecteplase)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132226\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As with all drugs that may affect hemostasis, bleeding is the major adverse effect associated with alteplase. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the dosage administered, concurrent use of multiple agents that alter hemostasis, and patient predisposition. Rapid lysis of coronary artery thrombi by thrombolytic agents may be associated with reperfusion-related atrial and/or ventricular arrhythmia. Lowest rate of bleeding complications expected with dose used to restore catheter function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">&gt;10%: Local: Catheter site hemorrhage (15%; accelerated administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal hemorrhage (5%), gastric ulcer with hemorrhage (4%), nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Genitourinary tract hemorrhage (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (GUSTO trial; minor: 7%; major: &lt;1%), bruise (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1% (Limited to important or life-threatening): Angioedema (orolingual), epistaxis, gingival hemorrhage, hypersensitivity reaction (including anaphylaxis, anaphylactoid reaction, laryngeal edema, skin rash, urticaria), intracranial hemorrhage (when adult dose is &le;100 mg), retroperitoneal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional events associated <b>with use in STEMI:</b> Asystole, atrioventricular block, atrioventricular dissociation, bradycardia, cardiac failure, cardiac tamponade, cardiogenic shock, ischemia (recurrent), mitral valve insufficiency, myocardial reinfarction, myocardial rupture, pericardial effusion, pericarditis, pulmonary edema, seizure, thromboembolism, ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional events associated <b>with use in pulmonary embolism:</b> Pleural effusion, pulmonary edema, pulmonary embolism (re-embolization), thromboembolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional events associated with use in stroke: Cerebral edema, cerebral herniation, cerebrovascular accident (new ischemic stroke), seizure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132240\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to alteplase or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Treatment of STEMI or PE:</b> Active internal bleeding; history of recent stroke; recent (within 3 months [ACCF/AHA: Within 2 months]) intracranial or intraspinal surgery or serious head trauma; presence of intracranial conditions that may increase the risk of bleeding (eg, intracranial neoplasm, arteriovenous malformation, aneurysm); known bleeding diathesis; severe uncontrolled hypertension (ACCF/AHA: Unresponsive to emergency therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Additional absolute contraindications (ACCF/AHA [O&rsquo;Gara 2013]; Kearon 2012; Kearon 2016):</i> Active bleeding (excluding menses); any prior intracranial hemorrhage; suspected aortic dissection; ischemic stroke within 3 months <b>except</b> when within 4.5 hours; significant closed head or facial trauma within 3 months with radiographic evidence of bony fracture or brain injury</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Treatment of AIS:</b> Current intracranial hemorrhage; subarachnoid hemorrhage; active internal bleeding; recent (within 3 months) intracranial or intraspinal surgery or serious head trauma; presence of intracranial conditions that may increase the risk of bleeding (eg, intracranial neoplasm, arteriovenous malformation, aneurysm); known bleeding diathesis; severe uncontrolled hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Additional contraindications (AHA/ASA [Jauch 2013]):</i> History of intracranial hemorrhage; suspicion of subarachnoid hemorrhage; stroke within 3 months; arterial puncture at a noncompressible site in previous 7 days; uncontrolled hypertension at time of treatment (eg, &gt;185 mm Hg systolic or &gt;110 mm Hg diastolic); multilobar cerebral infarction (hypodensity &gt;<sup>1</sup>/<sub>3</sub> cerebral hemisphere); known bleeding diathesis including but not limited to current use of oral anticoagulants with an INR &gt;1.7 (or PT &gt;15 seconds), current use of direct thrombin inhibitors or direct factor Xa inhibitors with elevated sensitive laboratory tests (eg, aPTT, INR, ECT, TT, or appropriate factor Xa activity assays) (See &ldquo;<b>Note</b>&rdquo;), administration of heparin within 48 hours preceding the onset of stroke with an elevated aPTT greater than the upper limit of normal, or platelet count &lt;100,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The AHA/ASA 2013 guidelines do allow the use of alteplase in patients taking direct thrombin inhibitors (eg, dabigatran) or direct factor Xa inhibitors (eg, rivaroxaban) when sensitive laboratory tests (eg, aPTT, INR, ECT, TT, or appropriate direct factor Xa activity assays) are normal or the patient has not received a dose of these agents for &gt;2 days (assuming normal renal function) (Jauch 2013). The AHA/ASA 2016 scientific statement states that alteplase is not recommended in patients who have received LMWH treatment doses within the previous 24 hours (AHA/ASA [Demaerschalk 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Additional exclusion criteria within clinical trials:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Presentation &lt;3 hours after initial symptoms (NINDS, 1995): Time of symptom onset unknown, rapidly improving or minor symptoms, major surgery within 2 weeks, GI or urinary tract hemorrhage within 3 weeks, aggressive treatment required to lower blood pressure, glucose level &lt;50 or &gt;400 mg/dL, and lumbar puncture within 1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> The AHA/ASA 2016 scientific statement recommends alteplase use in patients presenting &lt;3 hours after initial symptoms with mild but disabling stroke symptoms in the opinion of the treating physician. Alteplase is also reasonable in patients presenting &lt;3 hours after initial symptoms with moderate-to-severe ischemic stroke who demonstrate early improvement, but remain moderately impaired and potentially disabled in the examiner's judgment (AHA/ASA [Demaerschalk 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Presentation 3 to 4.5 hours after initial symptoms (AHA/ASA [Jauch 2013]; ECASS-III; Hacke 2008; Powers 2015): Age &gt;80 years, time of symptom onset unknown, rapidly improving or minor symptoms, current use of oral anticoagulants regardless of INR, glucose level &lt;50 or &gt;400 mg/dL, aggressive intravenous treatment required to lower blood pressure, major surgery or severe trauma within 3 months, baseline National Institutes of Health Stroke Scale (NIHSS) score &gt;25 [ie, severe stroke], and history of both stroke and diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> The AHA/ASA 2016 scientific statement has provided updated evidence on certain patients presenting in the 3 to 4.5 hour after initial symptoms window excluded in the aforementioned earlier guidelines, including: patients &gt;80 years (alteplase use in the 3 to 4.5 window can be safe and as effective as younger patients); patients taking warfarin with an INR &lt;1.7 (alteplase use appears safe and may be beneficial); patients with a history of both stroke and diabetes (alteplase use may be as effective as treatment in the 0 to 3 hour window, and may be a reasonable option) (AHA/ASA [Demaerschalk 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132223\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arrhythmias: Coronary thrombolysis may result in reperfusion arrhythmias (eg, accelerated idioventricular rhythm) (Miller 1986).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Internal bleeding (intracranial, retroperitoneal, gastrointestinal, genitourinary, respiratory) or external bleeding, especially at arterial and venous puncture, sites may occur (may be fatal). The total dose should not exceed 90 mg for acute ischemic stroke or 100 mg for acute myocardial infarction or pulmonary embolism. Doses &ge;150 mg associated with significantly increased risk of intracranial hemorrhage compared to doses &le;100 mg. Bleeding risk is low. Monitor all potential bleeding sites; if serious bleeding occurs, the infusion of alteplase and any other concurrent anticoagulants (eg, heparin) should be stopped.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cholesterol embolization: Has been reported rarely in patients treated with thrombolytic agents; may present with livedo reticularis, &ldquo;purple toe&rdquo; syndrome, acute renal failure, gangrenous digits, hypertension, pancreatitis, myocardial infarction, cerebral infarction, spinal cord infarction, retinal artery occlusion, bowel infarction, or rhabdomyolysis and can be fatal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orolingual angioedema: Although typically mild and transient, orolingual angioedema has occurred during and up to 2 hours after alteplase infusion in patients treated for AIS and STEMI. The use of concomitant ACE inhibitors and strokes involving the insular and frontal cortex are associated with an increased risk (Foster-Goldman 2013). The manufacturer recommends monitoring patients during and for several hours after infusion for orolingual angioedema. If angioedema develops, discontinue the infusion and promptly institute appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conditions that increase bleeding risk: For the following conditions, the risk of bleeding is higher with use of thrombolytics and should be weighed against the benefits of therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>&bull; PE: </i>Systolic BP &gt;180 mm Hg or diastolic BP &gt;110 mm Hg; recent bleeding (nonintracranial); recent surgery or invasive procedure; ischemic stroke &gt;3 months previously; anticoagulated (eg, VKA therapy); traumatic CPR; pericarditis or pericardial fluid; diabetic retinopathy; age &gt;75 years of age; low body weight (&lt;60 kg); female; black race (Kearon 2012; Kearon 2016); lumbar puncture within 10 days (ASRA [Horlocker 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>&bull; STEMI: </i>History of chronic, severe, poorly controlled hypertension; significant hypertension on presentation (systolic BP &gt;180 mm Hg or diastolic BP &gt;110 mm Hg); history of prior ischemic stroke &gt;3 months; dementia; traumatic or prolonged CPR (&gt;10 minutes); major surgery (&lt;3 weeks); recent internal bleeding (within 2 to 4 weeks); noncompressible vascular punctures; active peptic ulcer; oral anticoagulant therapy (ACCF/AHA [O&rsquo;Gara 2013]); lumbar puncture within 10 days (ASRA [Horlocker 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; End-stage renal disease: In the treatment of AIS, according to the AHA/ASA 2016 scientific statement, alteplase use is recommended in patients with end-stage renal disease on hemodialysis who have a normal aPTT (very limited populations evaluated). Patients with an elevated aPTT may have an increased risk for hemorrhagic complications (AHA/ASA [Demaerschalk 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ST-elevation myocardial infarction (STEMI): Appropriate use: Follow standard management for STEMI while infusing alteplase.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stroke: Appropriate use: Patients who present <b>within 3 hours</b> of stroke symptom onset should be treated with alteplase unless contraindications exist. A longer time window (<b>3 to 4.5 hours</b> after symptom onset) has been shown to be safe and efficacious for select individuals who meet ECASS III criteria (AHA/ASA [Demaerschalk 2016]; AHA/ASA [Jauch 2013]; Hacke 2008; Powers 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulants: Use with caution in patients receiving oral anticoagulants; increased risk of bleeding. According to the AHA/ASA 2013 guidelines, in the treatment of acute ischemic stroke (AIS) within 3 hours of symptom onset, the current use of oral anticoagulants producing an INR &gt;1.7, direct thrombin inhibitors, or direct factor Xa inhibitors with elevated sensitive laboratory test are contraindications. However, alteplase may be administered to patients with AIS having received direct thrombin inhibitors (eg, dabigatran) or direct factor Xa inhibitors (eg, rivaroxaban) when sensitive laboratory tests (eg, aPTT, INR, platelet count, ECT, TT, or appropriate direct factor Xa activity assays) are normal or the patient has not received a dose of these agents for &gt;2 days (assuming normal renal function). When treating AIS 3 to 4.5 hours after symptom onset, the use of alteplase should be avoided with current use of any oral anticoagulant regardless of INR (AHA/ASA [Jauch 2013]). However, according to the AHA/ASA 2016 scientific statement, when treating AIS 3 to 4.5 hours after symptom onset, the use of alteplase appears safe and may be beneficial for patients taking warfarin with an INR &lt;1.7 (AHA/AHA [Demaerschalk 2016]). In the treatment of STEMI, adjunctive use of parenteral anticoagulants (eg, enoxaparin, heparin, or fondaparinux) is recommended to improve vessel patency and prevent reocclusion and may also contribute to bleeding; monitor for bleeding (ACCF/AHA [O&rsquo;Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aspirin: In the treatment of acute ischemic stroke, avoid aspirin for 24 hours following administration of alteplase; administration within 24 hours increases the risk of hemorrhagic transformation. According to the AHA/ASA 2016 scientific statement, alteplase is recommended for patients taking antiplatelet drug monotherapy or antiplatelet combination therapy (eg, aspirin and clopidogrel) before stroke on the basis that the benefit outweighs a possible small increased risk of symptomatic intracerebral hemorrhage (sICH) (AHA/AHA [Demaerschalk 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heparin or low molecular weight heparin: Concurrent heparin anticoagulation may contribute to bleeding. In the treatment of acute ischemic stroke, concurrent use of anticoagulants was not permitted during the initial 24 hours of the &lt;3 hour window trial (NINDS 1995). The AHA/ASA does not recommend initiation of anticoagulant therapy within 24 hours of treatment with alteplase (AHA/ASA [Jauch 2013]). Initiation of SubQ heparin (&le;10,000 units) or equivalent doses of low molecular weight heparin for prevention of DVT during the first 24 hours of the 3 to 4.5 hour window trial was permitted and did not increase the incidence of intracerebral hemorrhage (Hacke 2008). Alteplase use is not recommended for acute ischemic stroke in patients who have received a treatment dose of LMWH within the previous 24 hours (AHA/ASA [Demaerschalk 2016]). For acute PE, withhold heparin during the 2-hour infusion period.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in patients with advanced age (eg, &gt;75 years); increased risk of bleeding. In the treatment of pulmonary embolism, age &gt;75 years is considered a relative contraindication (Kearon 2012; Kearon 2016). In the treatment of acute ischemic stroke (within 3 to 4.5 hours after symptom onset), alteplase use in patients &gt;80 years is considered an exclusion criteria (AHA/ASA [Jauch 2013]; Hacke 2008). However, according to the AHA/ASA 2016 scientific statement, alteplase use in patients &gt;80 years with acute ischemic stroke presenting within 3 to 4.5 hours after symptom onset is safe and can be as effective as in younger patients (AHA/ASA [Demaerschalk 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: Use with caution in pregnancy; increased risk of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cathflo Activase: When used to restore catheter function, use Cathflo cautiously in those patients with known or suspected catheter infections. Evaluate catheter for other causes of dysfunction before use. Avoid excessive pressure when instilling into catheter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Intramuscular injections and nonessential handling of the patient should be avoided. Venipunctures should be performed carefully and only when necessary. Avoid internal jugular and subclavian venous punctures. If arterial puncture is necessary, use an upper extremity vessel that can be manually compressed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Alteplase has not been shown to adequately treat underlying deep vein thrombosis in patients with PE. Consider the possible risk of re-embolization due to the lysis of underlying deep venous thrombi in this setting.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298716\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132228\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8478&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Thrombolytic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.  Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprotinin: May diminish the therapeutic effect of Thrombolytic Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran Etexilate.  Management: Carefully monitor for bleeding.  Dabigatran Canadian labeling recommends avoiding use with thrombolytic agents. Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran (see full drug monograph for details).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Thrombolytic Agents may enhance the anticoagulant effect of Desirudin.  Management: Discontinue treatment with thrombolytic agents prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Thrombolytic Agents. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Thrombolytic Agents. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: May decrease the serum concentration of Alteplase.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: Thrombolytic Agents may enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132230\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7872251\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. The risk of bleeding may be increased in pregnant women. Outcome information is available following alteplase use in pregnancy (Hirano 2013; Leonhardt 2006; Li 2012; &Ouml;zkan 2013). Currently, most guidelines consider pregnancy to be a relative contraindication for its use (ACCF/AHA [O&rsquo;Gara 2013]; AHA/ASA [Jauch 2013]; Kearon 2012; Kearon 2016; O'Connor 2010). Alteplase should not be withheld from pregnant women in life-threatening situations but should be avoided when safer alternatives are available (Bates 2012; Leonhardt 2006; Li 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20520342\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if alteplase is present in breast milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132232\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Acute ischemic stroke (AIS):</i> Baseline: Neurologic examination, head CT (without contrast), blood pressure, CBC, aPTT, PT/INR, glucose. During and after initiation: In addition to monitoring for bleeding complications, the 2013 AHA/ASA guidelines for the early management of AIS recommends the following: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Perform neurological assessments every 15 minutes during infusion and every 30 minutes thereafter for the next 6 hours, then hourly until 24 hours after treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">If severe headache, acute hypertension, nausea, or vomiting occurs, discontinue the infusion and obtain emergency CT scan. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Measure BP every 15 minutes for the first 2 hours of initiation then every 30 minutes for the next 6 hours, then hourly until 24 hours after initiation of alteplase. Increase frequency if a systolic BP is &ge;180 mm Hg or if a diastolic BP is &ge;105 mm Hg; administer antihypertensive medications to maintain BP at or below these levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Obtain a follow-up CT scan at 24 hours before starting anticoagulants or antiplatelet agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Central venous catheter clearance:</i> Assess catheter function by attempting to aspirate blood. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Pulmonary embolism:</i> Monitor BP and HR continually and for at least 24 hours after administration; assess invasive catheters hourly for bleeding (Smithburger 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>ST-elevation MI:</i> Baseline: Blood pressure, serum cardiac biomarkers, CBC, PT/INR, aPTT. During and after initiation: Assess for evidence of cardiac reperfusion through resolution of chest pain, resolution of baseline ECG changes, preserved left ventricular function, cardiac enzyme washout phenomenon, and/or the appearance of reperfusion arrhythmias; assess for bleeding potential through clinical evidence of GI bleeding, hematuria, gingival bleeding, fibrinogen levels, fibrinogen degradation products, PT and aPTT.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132222\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Initiates local fibrinolysis by binding to fibrin in a thrombus (clot) and converts entrapped plasminogen to plasmin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132239\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: &gt;50% present in plasma cleared ~5 minutes after infusion terminated, ~80% cleared within 10 minutes; fibrinolytic activity persists for up to 1 hour after infusion terminated (Semba 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub> (initial): Approximates plasma volume</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Initial: 5 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Clearance (in patients with acute MI receiving accelerated regimen): Rapidly from circulating plasma (572 &plusmn; 132 mL/minute) (Tanswell 1992), primarily hepatic; &gt;50% present in plasma is cleared within 5 minutes after the infusion is terminated, ~80% cleared within 10 minutes (Semba 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322973\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Activase Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $5,280.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $10,560.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cathflo Activase Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (1): $183.67</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132242\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actilyse (AE, AR, AT, AU, BD, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JO, KE, KR, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SV, SY, TH, TN, TR, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Activacin (JP);</li>\n      <li>Aktylize (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;A Comparison of Reteplase With Alteplase for Acute Myocardial Infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators,&rdquo; <i>N Engl J Med</i>, 1997, 337(16):1118-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/9340503/pubmed\" target=\"_blank\" id=\"9340503\">9340503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12015391\"></a>Abu-Laban RB, Christenson JM, Innes GD, et al. Tissue plasminogen activator in cardiac arrest with pulseless electrical activity [published correction appears in <i>N Engl J Med</i>. 2003;349(15):1487]. <i>N Engl J Med</i>. 2002;346(20):1522-1528.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/12015391/pubmed\" target=\"_blank\" id=\"12015391\">12015391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Activase (alteplase) [prescribing information] San Francisco, CA: Genentech; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alberts MJ, Bernstein RA, Naccarelli GV, et al, &ldquo;Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians,&rdquo; <i>Stroke</i>, 2012, 43(1):271-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/22156688/pubmed\" target=\"_blank\" id=\"22156688\">22156688</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12598079\"></a>Alpert JS. The thrombosed prosthetic valve: current recommendations based on evidence from the literature. <i>J Am Coll Cardiol</i>. 2003;41(4):659-660.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/12598079/pubmed\" target=\"_blank\" id=\"12598079\">12598079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Use of Intravenous tPA for Ischemic Stroke; Brown MD, Burton JH, Nazarian DJ, Promes SB. Clinical policy: use of intravenous tissue plasminogen activator for the management of acute ischemic stroke in the emergency department. <i>Ann Emerg Med</i>. 2015;66(3):322-333.e31. doi: 10.1016/j.annemergmed.2015.06.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/26304253/pubmed\" target=\"_blank\" id=\"26304253\">26304253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bates SM, Greer IA, Middeldorp S, et al, &quot;VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&quot; <i>Chest</i>, 2012, 141(2 Suppl):e691S-736S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/22315276/pubmed\" target=\"_blank\" id=\"22315276\">22315276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, Schonewille WJ; MR CLEAN Investigators, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. <i>N Engl J Med</i>. 2015;372(1):11-20. doi: 10.1056/NEJMoa1411587. Erratum in: <i>N Engl J Med</i>. 2015;22;372(4):394.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/25517348/pubmed\" target=\"_blank\" id=\"25517348\">25517348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonow RO, Carabello BA, Chatterjee K, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>J Am Coll Cardiol</i>. 2008;52(13):e1-e142.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/18848134/pubmed\" target=\"_blank\" id=\"18848134\">18848134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11377646\"></a>B&ouml;ttiger BW, Bode C, Kern S, et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. <i>Lancet</i>. 2001;357(9268):1583-1585.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/11377646/pubmed\" target=\"_blank\" id=\"11377646\">11377646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Broderick J, Connolly S, Feldmann E, et al, &ldquo;Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group,&rdquo; Stroke, 2007, 38(6):2001-23. Available at http://stroke.ahajournals.org/cgi/content/short/STROKEAHA.107.18368917478736</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bruen KJ, Ballard JR, Morris SE, Cochran A, Edelman LS, Saffle JR. Reduction of the incidence of amputation in frostbite injury with thrombolytic therapy. <i>Arch Surg</i>. 2007;142(6):546-551<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/17576891/pubmed\" target=\"_blank\" id=\"17576891\">17576891</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cathflo Activase (alteplase) [prescribing information] San Francisco, CA: Genentech; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chan J, Rees CR, Song AK, et al, &ldquo;Usefulness of Catheter-Directed Thrombolysis Using Alteplase in Peripheral Vascular Occlusion,&rdquo; Proc (Bayl Univ Med Cent), 2001, 14(1):3-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/16369579/pubmed\" target=\"_blank\" id=\"16369579\">16369579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22345500\"></a>Christoforidis GA, Slivka A, Mohammad Y, Karakasis C, Kontzialis M, Khadir M. Reperfusion rates following intra-arterial thrombolysis for acute ischemic stroke: the influence of the method for alteplase delivery. <i>AJNR Am J Neuroradiol</i>. 2012;33(7):1292-1298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/22345500/pubmed\" target=\"_blank\" id=\"22345500\">22345500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Colice GL, Curtis A, Deslauriers J, et al, &ldquo;Medical and Surgical Treatment of Parapneumonic Effusions: An Evidence-Based Guideline,&rdquo; <i>Chest</i>, 2000, 118(4):1158-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/11035692/pubmed\" target=\"_blank\" id=\"11035692\">11035692</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Comerota AJ and Schmieder FA, &ldquo;Intraoperative Lytic Therapy: Agents and Methods of Administration,&rdquo; <i>Semin Vasc Surg</i>, 2001, 14(2):132-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/11400089/pubmed\" target=\"_blank\" id=\"11400089\">11400089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27777354\"></a>Correction. <i>Stroke</i>. 2016;47(11):e262. doi: 10.1161/STR.0000000000000110<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/27777354/pubmed\" target=\"_blank\" id=\"27777354\">27777354</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2016;47(11):e262]. <i>Stroke</i>. 2016;47(2): 581-641. doi: 10.1161/STR.0000000000000086.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/26696642/pubmed\" target=\"_blank\" id=\"26696642\">26696642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies HE, Davies RJ, Davies CW; BTS Pleural Disease Guideline Group. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. <i>Thorax</i>. 2010;65(suppl 2):ii41-ii53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/20696693/pubmed\" target=\"_blank\" id=\"20696693\">20696693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis SN, Vermeulen L, Banton J, et al, &ldquo;Activity and Dosage of Alteplase Dilution for Clearing Occlusions of Venous-Access Devices,&rdquo; <i>Am J Health Syst Pharm</i>, 2000, 57(11):1039-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/10876745/pubmed\" target=\"_blank\" id=\"10876745\">10876745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Disini L, Wilson P, and Cockburn JF, &ldquo;Successful Intra-Arterial Alteplase Infusion is a Predictor of 12-Month Limb Survival in Patients With Lower Limb Arterial Occlusion,&rdquo; <i>Clin Radiol</i>, 2008, 63(6):636-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/18455554/pubmed\" target=\"_blank\" id=\"18455554\">18455554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20016808\"></a>Er F, Nia AM, Gassanov N, Caglayan E, Erdmann E, Hoppe UC. Impact of rescue-thrombolysis during cardiopulmonary resuscitation in patients with pulmonary embolism. <i>PLoS One</i>. 2009;4(12):e8323. doi: 10.1371/journal.pone.0008323.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/20016808/pubmed\" target=\"_blank\" id=\"20016808\">20016808</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122 (18 Suppl 3):640-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foster-Goldman A, McCarthy D. Angioedema from recombinant TPA administration: case report and pathophysiology review. <i>Am J Ther</i>. 2013;20(6):691-693.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/24247033/pubmed\" target=\"_blank\" id=\"24247033\">24247033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Generali J and Cada DJ, &ldquo;Alteplase (t-PA) Bolus: Occluded Catheters,&rdquo; <i>Hospital Pharmacy</i>, 2001, 36(1):93-103.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. <i>Lancet</i>. 1988;2(8606):293-298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/2899718/pubmed\" target=\"_blank\" id=\"2899718\">2899718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22315257\"></a>Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18815396\"></a>Hacke W, Kaste M, Bluhmki E, et al, &quot;Thrombolysis With Alteplase 3 to 4.5 Hours After Acute Ischemic Stroke,&quot; <i>N Engl J Med</i>, 2008, 359(13):1317-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/18815396/pubmed\" target=\"_blank\" id=\"18815396\">18815396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamblin SE and Furmanek DL, &ldquo;Intrapleural Tissue Plasminogen Activator for the Treatment of Parapneumonic Effusion,&rdquo; <i>Pharmacotherapy</i>, 2010, 30(8):855-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/20653362/pubmed\" target=\"_blank\" id=\"20653362\">20653362</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hawkins JA, Scaife ES, Hillman ND, et al, &ldquo;Current Treatment of Pediatric Empyema,&rdquo; <i>Semin Thorac Cardiovasc Surg</i>, 2004, 16(3):196-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/15619185/pubmed\" target=\"_blank\" id=\"15619185\">15619185</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirano T. Acute revascularization therapy in pregnant patients. <i>Neurol Med Chir</i> (Tokyo). 2013;53(8):531-536.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/23979048/pubmed\" target=\"_blank\" id=\"23979048\">23979048</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsch AT, Haskal ZJ, Hertzer NR, et al, &ldquo;ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). A Collaborative Report of the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease),&rdquo; <i>Circulation </i>, 2006, 113(11):e463-654.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/16549646/pubmed\" target=\"_blank\" id=\"16549646\">16549646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). <i>Reg Anesth Pain Med</i>. 2010;35(1):64-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/20052816/pubmed\" target=\"_blank\" id=\"20052816\">20052816</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12668299\"></a>Janata K, Holzer M, K&uuml;rkciyan I, et al. Major bleeding complications in cardiopulmonary resuscitation: the place of thrombolytic therapy in cardiac arrest due to massive pulmonary embolism. <i>Resuscitation</i>. 2003;57(1):49-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/12668299/pubmed\" target=\"_blank\" id=\"12668299\">12668299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jauch EC, Saver JL, Adams HP Jr, et al, &ldquo;Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,&rdquo; <i>Stroke</i>, 2013, 44(3):870-947.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/23370205/pubmed\" target=\"_blank\" id=\"23370205\">23370205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;142(6):1698-1704]. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/22315268/pubmed\" target=\"_blank\" id=\"22315268\">22315268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/26867832/pubmed\" target=\"_blank\" id=\"26867832\">26867832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keeley EC, Boura JA, and Grines CL, &quot;Comparison of Primary and Facilitated Percutaneous Coronary Interventions for ST-Elevation Myocardial Infarction: Quantitative Review of Randomised Trials,&quot; <i>Lancet</i>, 2006, 367(9510):579-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/16488801/pubmed\" target=\"_blank\" id=\"16488801\">16488801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12374874\"></a>Konstantinides S, Geibel A, Heusel G, et al, &quot;Heparin Plus Alteplase Compared With Heparin Alone in Patients With Submassive Pulmonary Embolism,&quot; <i>N Engl J Med</i>, 2002, 347(15):1143-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/12374874/pubmed\" target=\"_blank\" id=\"12374874\">12374874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10826469\"></a>K&uuml;rkciyan I, Meron G, Sterz F, et al. Pulmonary embolism as a cause of cardiac arrest: presentation and outcome. <i>Arch Intern Med</i>. 2000;160(10):1529-1535.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/10826469/pubmed\" target=\"_blank\" id=\"10826469\">10826469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Landy C, Plancade D, Gagnon N, Schaeffer E, Nadaud J, Favier JC. Complication of intraosseous administration of systemic fibrinolysis for a massive pulmonary embolism with cardiac arrest. <i>Resuscitation</i>. 2012;83(6):e149-e150. doi: 10.1016/j.resuscitation.2012.01.044.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/22394696/pubmed\" target=\"_blank\" id=\"22394696\">22394696</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: Special circumstances of resuscitation: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care [published correction appears in <i>Circulation</i>. 2016;134(9):e122]. <i>Circulation</i>. 2015;132(18 Suppl 2):S501-S518. doi: 10.1161/CIR.0000000000000264.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/26472998/pubmed\" target=\"_blank\" id=\"26472998\">26472998</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11719132\"></a>Lederer W, Lichtenberger C, Pechlaner C, Kroesen G, Baubin M. Recombinant tissue plasminogen activator during cardiopulmonary resuscitation in 108 patients with out-of-hospital cardiac arrest. <i>Resuscitation</i>. 2001;50(1):71-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/11719132/pubmed\" target=\"_blank\" id=\"11719132\">11719132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leonard MC and Shermock KM, &ldquo;Using Efficacy, Safety, and Cost Data to Support a Formulary Decision Regarding Thrombolytic Therapy,&rdquo; <i>Semin Vasc Surg</i>, 2001, 14(2):150-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/11400091/pubmed\" target=\"_blank\" id=\"11400091\">11400091</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leonhardt G, Gaul C, Nietsch HH, et al, &quot;Thrombolytic Therapy in Pregnancy,&quot; <i>J Thromb Thrombolysis</i>, 2006, 21(3):271-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/16683220/pubmed\" target=\"_blank\" id=\"16683220\">16683220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li Y, Margraf J, Kluck B, et al, &quot;Thrombolytic Therapy For Ischemic Stroke Secondary to Paradoxical Embolism in Pregnancy: A Case Report and Literature Review,&quot; <i>Neurologist</i>, 2012, 18(1):44-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/22217616/pubmed\" target=\"_blank\" id=\"22217616\">22217616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Logan JK, Pantle H, Huiras P, Bessman E, Bright L. Evidence-based diagnosis and thrombolytic treatment of cardiac arrest or periarrest due to suspected pulmonary embolism. <i>Am J Emerg Med</i>. 2014;32(7):789-96. doi: 10.1016/j.ajem.2014.04.032.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/24856738/pubmed\" target=\"_blank\" id=\"24856738\">24856738</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lundergan CF, Reiner JS, McCarthy WF, et al, &ldquo;Clinical Predictors of Early Infarct-Related Artery Patency Following Thrombolytic Therapy: Importance of Body Weight, Smoking History, Infarct-Related Artery and Choice of Thrombolytic Regimen: The GUSTO-I Experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries,&rdquo; <i>J Am Coll Cardiol</i>, 1998, 32(3):641-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/9741505/pubmed\" target=\"_blank\" id=\"9741505\">9741505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller FC, Krucoff MW, Satler LF, et al. Ventricular arrhythmias during reperfusion. <i>Am Heart J</i>. 1986;112(5):928-932.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/3776819/pubmed\" target=\"_blank\" id=\"3776819\">3776819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Connor RE, Brady W, Brooks SC, et al, &ldquo;Part 10: Acute Coronary Syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):787-817.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/20956226/pubmed\" target=\"_blank\" id=\"20956226\">20956226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ouriel K, &ldquo;Current Status of Thrombolysis for Peripheral Arterial Occlusive Disease,&rdquo; <i>Ann Vasc Surg</i>, 2002, 16(6):797-804.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/12391507/pubmed\" target=\"_blank\" id=\"12391507\">12391507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ouriel K and Kandarpa K, &ldquo;Safety of Thrombolytic Therapy With Urokinase or Recombinant Tissue Plamsminogen Activator for Peripheral Arterial Occlusion: A Comprehensive Compilation of Published Work,&rdquo; <i>J Endovasc Ther</i>, 2004, 11(4):436-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/15298504/pubmed\" target=\"_blank\" id=\"15298504\">15298504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Ouml;zkan M, &Ccedil;akal B, Karakoyun S, et al. Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator. <i>Circulation</i>. 2013;128(5):532-540. doi: 10.1161/CIRCULATIONAHA.113.001145.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/23812180/pubmed\" target=\"_blank\" id=\"23812180\">23812180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Piazza G, Hohlfelder B, Jaff MR, et al; SEATTLE II Investigators. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II Study. <i>JACC Cardiovasc Interv</i>. 2015;8(10):1382-1392. doi: 10.1016/j.jcin.2015.04.020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/26315743/pubmed\" target=\"_blank\" id=\"26315743\">26315743</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ponec D, Irwin D, Haire WD, et al, &ldquo;Recombinant Tissue Plasminogen Activator (Alteplase) for Restoration of Flow in Occluded Central Venous Access Devices: A Double-Blind Placebo-Controlled Trial - The Cardiovascular Thrombolytic to Open Occluded Lines (COOL) Efficacy Trial,&rdquo; <i>J Vasc Interv Radiol</i>, 2001, 12(8):951-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/11487675/pubmed\" target=\"_blank\" id=\"11487675\">11487675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17729010\"></a>Poncyljusz W, Falkowski A, Kojder I, et al. Treatment of acute ischemic brain infarction with the assistance of local intraarterial thrombolysis with recombinant tissue-type plasminogen activator. <i>Acta Radiol</i>. 2007;48(7):774-780.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/17729010/pubmed\" target=\"_blank\" id=\"17729010\">17729010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, Johnston KC; American Heart Association Stroke Council, et al. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. <i>Stroke</i>. 2015;46(10):3020-35. doi: 10.1161/STR.0000000000000074.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/26123479/pubmed\" target=\"_blank\" id=\"26123479\">26123479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rahman NM, Maskell NA, West A, et al, &ldquo;Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection,&rdquo; <i>N Engl J Med</i>, 2011, 365(6):518-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/21830966/pubmed\" target=\"_blank\" id=\"21830966\">21830966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Results of a Prospective, Randomised Trial Evaluating Surgery Versus Thrombolysis for Ischemia of the Lower Extremity. The STILE Trial,&rdquo; <i>Ann Surg</i>, 1994, 220(3):251-66; discussion 266-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/8092895/pubmed\" target=\"_blank\" id=\"8092895\">8092895</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12598078\"></a>Roudaut R, Lafitte S, Roudaut MF, et al. Fibrinolysis of mechanical prosthetic valve thrombosis: a single-center study of 127 cases. <i>J Am Coll Cardiol</i>. 2003;41(4):653-658.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/12598078/pubmed\" target=\"_blank\" id=\"12598078\">12598078</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10735420\"></a>Semba CP, Bakal CW, Calis KA, et al, &ldquo;Alteplase as an Alternative to Urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy,&rdquo; <i>J Vasc Interv Radiol</i>, 2000, 11(3):279-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/10735420/pubmed\" target=\"_blank\" id=\"10735420\">10735420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27422214\"></a>Sharifi M, Berger J, Beeston P, Bay C, Vajo Z, Javadpoor S; &quot;PEAPETT&quot; investigators. Pulseless electrical activity in pulmonary embolism treated with thrombolysis (from the &quot;PEAPETT&quot; study). <i>Am J Emerg Med</i>. 2016;34(10):1963-1967. doi: 10.1016/j.ajem.2016.06.094.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/27422214/pubmed\" target=\"_blank\" id=\"27422214\">27422214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smithburger PL, Campbell S, Kane-Gill SL. Alteplase treatment of acute pulmonary embolism in the intensive care unit [published correction appears in <i>Crit Care Nurse</i>. 2013;33(3):12].<i>Crit Care Nurse</i>. 2013;33(2):17-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/23547122/pubmed\" target=\"_blank\" id=\"23547122\">23547122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    St Peter SD, Tsao, K, Harrison C, et al, &ldquo;Thorascopic Decortication vs Tube Thoracostomy With Fibrinolysis for Empyema in Children: A Prospective, Randomized Trial,&rdquo; <i>J Pediatr Surg</i>, 2009, 44(1):106-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/19159726/pubmed\" target=\"_blank\" id=\"19159726\">19159726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sugimoto K, Hofmann LV, Razavi MK, et al, &ldquo;The Safety, Efficacy, and Pharmacoeconomics of Low-Dose Alteplase Compared With Urokinase for Catheter-Directed Thrombolysis of Arterial and Venous Occlusions,&rdquo; <i>J Vasc Surg</i>, 2003, 37(3):512-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/12618684/pubmed\" target=\"_blank\" id=\"12618684\">12618684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tanswell P, Tebbe U, Neuhaus K, et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. <i>J Am Coll Cardiol</i>. 1992;19(5):1071-1075.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/1372625/pubmed\" target=\"_blank\" id=\"1372625\">1372625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    The Gusto Angiographic Investigators, &ldquo;The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival After Acute Myocardial Infarction,&rdquo; <i>N Engl J Med</i>, 1993, 329(22):1615-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/8232430/pubmed\" target=\"_blank\" id=\"8232430\">8232430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thommi G, Nair CK, Aronow WS, Shehan C, Meyers P, McLeay M. Efficacy and safety of intrapleural instillation of alteplase in the management of complicated pleural effusion or empyema. <i>Am J Ther</i>. 2007;14(4):341-345.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/17667208/pubmed\" target=\"_blank\" id=\"17667208\">17667208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thommi G, Shehan JC, Robison KL, Christensen M, Backemeyer LA, McLeay MT. A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. <i>Respir Med</i>. 2012;106(5):716-723.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/22398159/pubmed\" target=\"_blank\" id=\"22398159\">22398159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Thrombolysis in the Management of Lower Limb Peripheral Arterial Occlusion - A Consensus Document. Working Party on Thrombolysis in the Management of Limb Ischemia,&rdquo; <i>J Vasc Interv Radiol</i>, 2003, 14(9 Pt 2):337-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/14514841/pubmed\" target=\"_blank\" id=\"14514841\">14514841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Tissue Plasminogen Activator for Acute Ischemic Stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group,&rdquo; <i>N Engl J Med</i>, 1995, 333(24):1581-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/7477192/pubmed\" target=\"_blank\" id=\"7477192\">7477192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topol EJ, &ldquo;Reperfusion Therapy for Acute Myocardial Infarction With Fibrinolytic Therapy or Combination Reduced Fibrinolytic Therapy and Platelet Glycoprotein IIb/IIIa Inhibition: The GUSTO V Randomized Trial. GUSTO V Investigators,&rdquo; <i>Lancet</i>, 2001, 357(9272):1905-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/11425410/pubmed\" target=\"_blank\" id=\"11425410\">11425410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17917723\"></a>Tountopoulou A, Ahl B, Weissenborn K, Becker H, Goetz F. Intra-arterial thrombolysis using rt-PA in patients with acute stroke due to vessel occlusion of anterior and/or posterior cerebral circulation. <i>Neuroradiology</i>. 2008;50(1):75-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/17917723/pubmed\" target=\"_blank\" id=\"17917723\">17917723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):829-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vedantham S, Goldhaber SZ, Julian JA, et al; ATTRACT Trial Investigators. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. <i>N Engl J Med</i>. 2017;377(23):2240-2252. doi: 10.1056/NEJMoa1615066.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/29211671/pubmed\" target=\"_blank\" id=\"29211671\">29211671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vincze Z, Brugos B. Does impairment of renal and hepatic function influence the metabolism of thrombolytics in patients with myocardial infarction? <i>Pharmazie</i>. 2008;63(3):245-246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/18444516/pubmed\" target=\"_blank\" id=\"18444516\">18444516</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang TF, Squizzato A, Dentali F, Ageno W. The role of thrombolytic therapy in pulmonary embolism. <i>Blood</i>. 2015;125(14):2191-2199. doi: 10.1182/blood-2014-08-559278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/25631770/pubmed\" target=\"_blank\" id=\"25631770\">25631770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zacharias JM, Weatherston CP, Spewak CR, et al, &ldquo;Alteplase Versus Urokinase for Occluded Hemodialysis Catheters,&rdquo; <i>Ann Pharmacother</i>, 2003, 37(1):27-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-drug-information/abstract-text/12503929/pubmed\" target=\"_blank\" id=\"12503929\">12503929</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8478 Version 166.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F132252\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F132253\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F132301\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F50663670\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F132279\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F132258\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15671450\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671451\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F132234\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F132219\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F132237\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14471277\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14471278\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F132236\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475022\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F132309\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F132226\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F132240\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F132223\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298716\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F132228\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F132230\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7872251\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20520342\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F132232\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F132222\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F132239\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322973\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F132242\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8478|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=alteplase-patient-drug-information\" class=\"drug drug_patient\">Alteplase: Patient drug information</a></li><li><a href=\"topic.htm?path=alteplase-pediatric-drug-information\" class=\"drug drug_pediatric\">Alteplase: Pediatric drug information</a></li></ul></div></div>","javascript":null}